The more infectious variant dominating coronavirus infection i | Financial Times Ukraine news

The more infectious variant dominating coronavirus infection in the UK is evolving further mutations, which scientists say could make existing vaccines less effective at preventing infection.

Pfizer now expects about $15bn in revenue this year from its Covid-19 vaccine developed with BioNTech, as it benefits from having the first shot approved in the west.

Russia’s flagship vaccine Sputnik V has shown 91.6% efficacy against symptomatic Covid-19 in clinical trials. It's only the third with efficacy of more than 90%. Take out a trial subscription to read more.